Sign up to save your podcasts
Or
Share Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis (MG), Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis (MG), Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials
Elie Naddaf, MD, interviews James Howard, MD, about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis (MG), highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.
View all episodes
By AANEM
4.9
2525 ratings
Elie Naddaf, MD, interviews James Howard, MD, about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis (MG), highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.
More shows like American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
View all
The Art of Manliness
14,277 Listeners
Neurology® Podcast
297 Listeners
Practical Neurology Podcast
51 Listeners
The Curbsiders Internal Medicine Podcast
3,338 Listeners
Bold Names
1,448 Listeners
The Peter Attia Drive
8,893 Listeners
Neurology Minute
132 Listeners
Neurology Exam Prep Podcast
179 Listeners
Chasing Life
8,183 Listeners
The Medbullets Step 2 & 3 Podcast
113 Listeners
The Curious Clinicians
369 Listeners
Neurology @Point of Care Podcasts
10 Listeners
The Dr. Gabrielle Lyon Show
1,180 Listeners
Continuum Audio
79 Listeners
Your Brain On
305 Listeners